Evidence map›Paper›PMID 33601915›Full record

ArticleHip international : the journal of clinical and experimental research on hip pathology and therapy2022

Revision and 90-day mortality following hip arthroplasty in patients with inflammatory arthritis and ankylosing spondylitis enrolled in the National Joint Registry for England and Wales.

Laura L Miller, Daniel Prieto-Alhambra, Lea Trela-Larsen, J Mark Wilkinson, Emma M Clark, Ashley W Blom, Alexander J MacGregor

Open access · hybridAbstract read
In one paragraph

Article in Hip international : the journal of clinical and experimental research on hip pathology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Laura L MillerMusculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Bristol, UK.
Daniel Prieto-AlhambraMusculoskeletal Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Lea Trela-LarsenMusculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Bristol, UK.
J Mark WilkinsonDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Emma M ClarkMusculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Bristol, UK.
Ashley W BlomMusculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Bristol, UK.
Alexander J MacGregorNorwich Medical School, University of East Anglia, Norwich, UK.ORCID https://orcid.org/0000-0003-2163-2325
University of Bristol · GBNuffield Orthopaedic Centre · GBUniversity of East Anglia · GBUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess revision rates and postoperative mortality in patients undergoing hip arthroplasty (HA) for inflammatory arthritis compared to hip osteoarthritis (OA).

methodsThe analysis was conducted among cases of HA that were recorded in the National Joint Registry for England and Wales (NJR) between April 2003 and December 2012 and linked to Office for National Statistics mortality records. Procedures were identified where the indication for surgery was listed as seropositive rheumatoid arthritis (RA), ankylosing spondylitis (AS), other inflammatory arthritis (otherIA), or OA. 5-year revision risk and 90-day postoperative mortality according to indication were compared using Cox regression models adjusted for age, sex, American Society of Anaesthesiologists (ASA) grade, year of operation, implant type, and surgical approach.

resultsThe cohort included 1457 HA procedures conducted for RA, 615 for AS, 1000 for otherIA, and 183,108 for OA. When compared with OA, there was no increased revision risk for any form of inflammatory arthritis (adjusted HRs: RA: 0.93 (0.64-1.35); AS: 1.14 (0.73-1.79); otherIA: 1.08 (0.73-1.59)). Postoperative 90-day mortality was increased for RA when compared with OA (adjusted HR: 2.86 (1.68-4.88)), but not for AS (adjusted HR: 1.56 (0.59-4.18)) or otherIA (adjusted HR: 0.64 (0.16-2.55)).

conclusionsThe revision risk in HA performed for all types of inflammatory arthritis is similar to that for HA performed for OA. The 3-fold increased risk of 90-day mortality in patients with RA compared with OA highlights the need for active management of associated comorbidities in RA patients during the perioperative period.

Indexed as

Arthroplasty, Replacement, HipArthroplasty, Replacement, KneeSpondylitis, AnkylosingHumansRegistriesReoperationWalesAnkylosing spondylitiship arthroplastymortalityosteoarthritisrevisionrheumatoid arthritis

Identifiers

PMID33601915
PMCPMC9096577
OpenAlexW3131806514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.